Cargando…

The JmjN domain as a dimerization interface and a targeted inhibitor of KDM4 demethylase activity

Histone methylation is regulated to shape the epigenome by modulating DNA compaction, thus playing central roles in fundamental chromatin-based processes including transcriptional regulation, DNA repair and cell proliferation. Histone methylation is erased by demethylases including the well-establis...

Descripción completa

Detalles Bibliográficos
Autores principales: Levin, May, Stark, Michal, Assaraf, Yehuda G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908291/
https://www.ncbi.nlm.nih.gov/pubmed/29682190
http://dx.doi.org/10.18632/oncotarget.24717
_version_ 1783315694617624576
author Levin, May
Stark, Michal
Assaraf, Yehuda G.
author_facet Levin, May
Stark, Michal
Assaraf, Yehuda G.
author_sort Levin, May
collection PubMed
description Histone methylation is regulated to shape the epigenome by modulating DNA compaction, thus playing central roles in fundamental chromatin-based processes including transcriptional regulation, DNA repair and cell proliferation. Histone methylation is erased by demethylases including the well-established KDM4 subfamily members, however, little is known about their dimerization capacity and its impact on their demethylase activity. Using the powerful bimolecular fluorescence complementation technique, we herein show the in situ formation of human KDM4A and KDM4C homodimers and heterodimers in nuclei of live transfectant cells and evaluate their H3K9me3 demethylation activity. Using size exclusion HPLC as well as Western blot analysis, we show that endogenous KDM4C undergoes dimerization under physiological conditions. Importantly, we identify the JmjN domain as the KDM4C dimerization interface and pin-point specific charged residues therein to be essential for this dimerization. We further demonstrate that KDM4A/C dimerization is absolutely required for their demethylase activity which was abolished by the expression of free JmjN peptides. In contrast, KDM4B does not dimerize and functions as a monomer, and hence was not affected by free JmjN expression. KDM4 proteins are overexpressed in numerous malignancies and their pharmacological inhibition or depletion in cancer cells was shown to impair tumor cell proliferation, invasion and metastasis. Thus, the KDM4 dimer-interactome emerging from the present study bears potential implications for cancer therapeutics via selective inhibition of KDM4A/C demethylase activity using JmjN-based peptidomimetics.
format Online
Article
Text
id pubmed-5908291
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-59082912018-04-20 The JmjN domain as a dimerization interface and a targeted inhibitor of KDM4 demethylase activity Levin, May Stark, Michal Assaraf, Yehuda G. Oncotarget Research Paper Histone methylation is regulated to shape the epigenome by modulating DNA compaction, thus playing central roles in fundamental chromatin-based processes including transcriptional regulation, DNA repair and cell proliferation. Histone methylation is erased by demethylases including the well-established KDM4 subfamily members, however, little is known about their dimerization capacity and its impact on their demethylase activity. Using the powerful bimolecular fluorescence complementation technique, we herein show the in situ formation of human KDM4A and KDM4C homodimers and heterodimers in nuclei of live transfectant cells and evaluate their H3K9me3 demethylation activity. Using size exclusion HPLC as well as Western blot analysis, we show that endogenous KDM4C undergoes dimerization under physiological conditions. Importantly, we identify the JmjN domain as the KDM4C dimerization interface and pin-point specific charged residues therein to be essential for this dimerization. We further demonstrate that KDM4A/C dimerization is absolutely required for their demethylase activity which was abolished by the expression of free JmjN peptides. In contrast, KDM4B does not dimerize and functions as a monomer, and hence was not affected by free JmjN expression. KDM4 proteins are overexpressed in numerous malignancies and their pharmacological inhibition or depletion in cancer cells was shown to impair tumor cell proliferation, invasion and metastasis. Thus, the KDM4 dimer-interactome emerging from the present study bears potential implications for cancer therapeutics via selective inhibition of KDM4A/C demethylase activity using JmjN-based peptidomimetics. Impact Journals LLC 2018-03-30 /pmc/articles/PMC5908291/ /pubmed/29682190 http://dx.doi.org/10.18632/oncotarget.24717 Text en Copyright: © 2018 Levin et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Levin, May
Stark, Michal
Assaraf, Yehuda G.
The JmjN domain as a dimerization interface and a targeted inhibitor of KDM4 demethylase activity
title The JmjN domain as a dimerization interface and a targeted inhibitor of KDM4 demethylase activity
title_full The JmjN domain as a dimerization interface and a targeted inhibitor of KDM4 demethylase activity
title_fullStr The JmjN domain as a dimerization interface and a targeted inhibitor of KDM4 demethylase activity
title_full_unstemmed The JmjN domain as a dimerization interface and a targeted inhibitor of KDM4 demethylase activity
title_short The JmjN domain as a dimerization interface and a targeted inhibitor of KDM4 demethylase activity
title_sort jmjn domain as a dimerization interface and a targeted inhibitor of kdm4 demethylase activity
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908291/
https://www.ncbi.nlm.nih.gov/pubmed/29682190
http://dx.doi.org/10.18632/oncotarget.24717
work_keys_str_mv AT levinmay thejmjndomainasadimerizationinterfaceandatargetedinhibitorofkdm4demethylaseactivity
AT starkmichal thejmjndomainasadimerizationinterfaceandatargetedinhibitorofkdm4demethylaseactivity
AT assarafyehudag thejmjndomainasadimerizationinterfaceandatargetedinhibitorofkdm4demethylaseactivity
AT levinmay jmjndomainasadimerizationinterfaceandatargetedinhibitorofkdm4demethylaseactivity
AT starkmichal jmjndomainasadimerizationinterfaceandatargetedinhibitorofkdm4demethylaseactivity
AT assarafyehudag jmjndomainasadimerizationinterfaceandatargetedinhibitorofkdm4demethylaseactivity